← Patent-cliff monitor small molecule WEGOVY FLEXTOUCH SEMAGLUTIDE
Loss of exclusivity May 2040 latest FDA-listed patent expiry
Company NOVO NORDISK INC
Drug detail Brand name WEGOVY FLEXTOUCH Active ingredient SEMAGLUTIDE Strength 9.6MG/3ML (3.2MG/ML) Dosage form SOLUTION Route SUBCUTANEOUS Modality Small molecule FDA approval June 2026 Marketing status RX
Listed patents Patent Expires Type 11478533 May 2040 use U-3861 12551536 October 2038 use U-4418 12029779 October 2038 use U-3162 9764003 June 2033 use U-3161 8129343 December 2031 substance, product
Regulatory exclusivity Code Expires I-973 August 2028 I-935 March 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.